Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/05/21
Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe DiseaseGlobeNewsWire • 04/05/21
Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 GangliosidosisGlobeNewsWire • 04/01/21
U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS DisordersGlobeNewsWire • 03/08/21
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/03/21
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/03/21
Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021GlobeNewsWire • 02/24/21
FDA Clears IND Application for Passage Bio's Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment OptionsGlobeNewsWire • 02/08/21
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin MutationsGlobeNewsWire • 01/28/21